merck - Search News

News

Merck, The Wall Street Journal

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments.

Bloomberg on MSN · 2h

Merck KGaA Nears Deal to Buy SpringWorks Therapeutics

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be identified discussing confidential information.

MarketWatch · 14h

SpringWorks Therapeutics Shares Rise Following WSJ Report of Merck KGaA Deal

Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock rose 8.7%, to $44.80, in afternoon trading Thursday. Shares are up 2.3% in the past year.

Merck lowers profit Outlook

Reuters on MSN · 23h

Merck Posts Higher Profit, Puts Tariffs Cost at $200 Million

For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share forecast to between $8.82 and $8.97, from a previous $8.88 to $9.03. Analysts have forecast 2025 earnings of $8.95 per share on revenue of $65 billion.

CNBC on MSN · 18h

Merck lowers profit outlook, partly due to $200 million expected tariff hit

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.

Crain's New York Business · 17h

Merck expects $200M tariff hit amid Gardasil fallout

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 billion analysts had predicted. Adjusted earnings of $2.22 per share outpaced expectations of $2.13 a share.

pharmaphorum47m

Merck puts a price on its SpringWorks takeover bid

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

21h

Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Fierce Pharma15h

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

1hon MSN

Health Care Roundup: Market Talk

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

22hon MSN

Merck Earnings Are Nearly Here. Concerns About Its Keytruda Patent Cliff Are Growing.

Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

Fierce Pharma18h

Merck ‘willing to work’ with Trump administration on price gap between US, international medicines

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Business Insider1d

Merck reports Q1 adjusted EPS $2.22, consensus $2.14

Davis, chairman and chief executive officer, Merck (MRK). “We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Merck, The Wall Street Journal

Merck lowers profit Outlook

Related topics